BEVERLY HILLS, Calif., Sept. 19, 2012 /PRNewswire/ -- Eaton Scientific Systems, Ltd. ("Eaton" or the "Company") a wholly-owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce that it has engaged Capital Group Communications, Inc. ("CGC") to assists the Company in an expanded investor relations strategy. CGC will assume the day-to-day investor relations functions and undertake a comprehensive program to introduce new potential investors to the Company.
"The addition of Capital Group to the Pristine and Eaton Scientific teams will assist us in supporting an expanded investor relations and communications effort within the investment community and the mainstream media," stated Michael Borkowski, CEO of Eaton Scientific. "We look forward to working with CGC to grow, service, and maintain our valuable shareholder base and to expose a larger audience to our compelling products and corporate growth potential."
San Francisco-based CGC is a leading consulting firm specializing in the creation and implementation of comprehensive investor, public and media relations for venture stage and emerging growth companies. CGC utilizes a long-term, collaborative business model whose strength has always been its relationships.
In addition, the Company has also recently launched several important new content features to its corporate website at www.eatonscientific.com. New features include detailed scientific information concerning Tropine 3 (Homatropine) and many new links/content/video related to the recent support and endorsement from leading women's sexual health expert, Dr. Jennifer R. Berman, MD. All shareholders and other interested parties are encouraged to visit the website to review the new material.
About Pristine Solutions, Inc.
Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non- hormonal treatment of hot flashes in pre-menopausal, peri- menopausal, and post-menopausal women. The company is preparing for Phase 1 & 2 Clinical Trials with the goal of FDA approval of Tropine 3.
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Eaton Scientific Systems, Ltd.